Abstract
Background: The poor outcome of advanced renal cell carcinoma (RCC) necessitates new treatments. Cobimetinib is a MEK inhibitor and approved for the t......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
